US FDA has withdrawn the approval of the NDA for Wellcovorin, at the request of GSK (GSK LN)
Context
The withdrawal of the NDA approval for Wellcovorin at the request of GSK suggests strategic recalibration from the company regarding its product pipeline. This may raise concerns about GSK's near-term prospects and could influence investor sentiment negatively, with potential ramifications for the stock and the broader pharmaceuticals sector. Keep an eye on how this affects GSK's market position and collaboration opportunities moving forward.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#UNITED KINGDOM#EUROPE#GLAXOSMITHKLINE PLC#GSK.LN#FDA#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#FTSE 100 INDEX#GSK PLC#GSK#FTSE 100